Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.43 |
| ▸ | KHK | P50053 | 6/20 | 0.42 |
| ▸ | QDPR | P09417 | 3/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18113568 | 0.99 | HTR2C (0.44) | HTR2CKHKQDPRALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL18113566 | 0.91 | ALOX5AP (0.44) | HTR2CKHKQDPRALOX5APFEN1 | |
| SCHEMBL20414655 | 0.91 | ALOX5AP (0.44) | HTR2CKHKQDPRALOX5APFEN1 | |
| SCHEMBL12373870 | 0.84 | HTR2C (0.49) | HTR2CKHKQDPRSIGMAR1 | |
| Hydrochloric Acid SCHEMBL2278255 | 0.82 | HTR2C (0.50) | HTR2CKHKQDPRSIGMAR1 | |
| Hydrochloric Acid SCHEMBL20395786 | 0.82 | HTR2C (0.50) | HTR2CKHKQDPRSIGMAR1 | |
| SCHEMBL20414657 | 0.81 | PDE3B (0.38) | ALOX5APFEN1 | |
| SCHEMBL1199994 | 0.79 | HTR2C (0.48) | HTR2CKHKQDPRALOX5APFEN1 | |
| SCHEMBL18121807 | 0.78 | MMP2 (0.35) | QDPRCCNT1CDK9SIGMAR1 | |
| SCHEMBL27025830 | 0.78 | HTR2C (0.47) | HTR2CKHKQDPRALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201380-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885KHK 2109/4885QDPR 2060/4885 |
| US-20180207132-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | HTR2C 2823/4885KHK 2109/4885QDPR 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.